Sequential therapy with bevacizumab and EGFR inhibitors for
metastatic colorectal carcinoma: a national registry-based
analysis

J 2019

Sequential therapy with bevacizumab and EGFR inhibitors for metastatic colorectal carcinoma: a national registry-based analysis

BUCHLER, Tomas; Renata CHLOUPKOVÁ; Alexandr POPRACH; Ondrej FIALA; Igor KISS et al.

Základní údaje

Originální název

Sequential therapy with bevacizumab and EGFR inhibitors for metastatic colorectal carcinoma: a national registry-based analysis

Autoři

Vydání

CANCER MANAGEMENT AND RESEARCH, ALBANY, DOVE MEDICAL PRESS LTD, 2019, 1179-1322

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Nový Zéland

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.886

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/19:00109476

Organizační jednotka

Lékařská fakulta

DOI

https://doi.org/10.2147/CMAR.S183093

UT WoS

000454529000001

EID Scopus

2-s2.0-85059478345

Klíčová slova anglicky

colorectal carcinoma; bevacizumab; panitumumab; cetuximab; sequence

Štítky

14110811, 14119612, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 11. 5. 2020 09:12, Mgr. Tereza Miškechová

Anotace

V originále

Purpose: Although inhibitors of vascular endothelial growth factor and inhibitors of epidermal growth factor receptor (EGFRi) are commonly used for the treatment of metastatic colorectal cancer (mCRC), the optimal sequencing of the agents is currently unclear. Methods: A national registry of targeted therapies was used to analyze baseline characteristics and outcomes of patients with mCRC and wild-type KRAS exon 2 status who received bevacizumab and EGFRi (cetuximab or panitumumab) as a part of first- and second-line treatment in either sequence. Results: The cohort included 490 patients (181 patients treated with first-line EGFRi and second-line bevacizumab and 309 patients treated with first-line bevacizumab and second-line EGFRi). Median overall survival (OS) from the initiation on first-line therapy was similar for patients treated with either sequence, reaching 31.8 (95% CI 27.5-36.1) vs 31.4 months (95% CI 27.8-35.0) for EGFRi -> bevacizumab vs bevacizumab -> EGFRi cohort, respectively. Time from first-line initiation to progression on the second-line therapy [progression-free survival (PFS)] was 21.1 (95% CI 19.3-23.0) vs 19.3 months (95% CI 17.3-21.3) for bevacizumab -> EGFRi vs EGFRi -> bevacizumab cohort, respectively (P=0.016). Conclusion: This retrospective analysis of real-world data of patients with wild-type KRAS exon 2 mCRC showed no differences in OS between cohorts treated with bevacizumab -> EGFRi vs the reverse sequence while combined PFS favored the bevacizumab -> EGFRi sequence.

Citovat

BUCHLER, Tomas; Renata CHLOUPKOVÁ; Alexandr POPRACH; Ondrej FIALA; Igor KISS; Katerina KOPECKOVA; Ladislav DUŠEK; Veronika VESKRNOVA; Lubomir SLAVICEK; Milan KOHOUTEK; Jindrich FINEK; Marek SVOBODA; Lubos PETRUZELKA a Bohuslav MELICHAR. Sequential therapy with bevacizumab and EGFR inhibitors for metastatic colorectal carcinoma: a national registry-based analysis. CANCER MANAGEMENT AND RESEARCH. ALBANY: DOVE MEDICAL PRESS LTD, 2019, roč. 11, č. 2019, s. 359-368. ISSN 1179-1322. Dostupné z: https://doi.org/10.2147/CMAR.S183093.

@article{1522176,
   author = {Buchler, Tomas and Chloupková, Renata and Poprach, Alexandr and Fiala, Ondrej and Kiss, Igor and Kopeckova, Katerina and Dušek, Ladislav and Veskrnova, Veronika and Slavicek, Lubomir and Kohoutek, Milan and Finek, Jindrich and Svoboda, Marek and Petruzelka, Lubos and Melichar, Bohuslav},
   article_location = {ALBANY},
   article_number = {2019},
   doi = {https://doi.org/10.2147/CMAR.S183093},
   keywords = {colorectal carcinoma; bevacizumab; panitumumab; cetuximab; sequence},
   language = {eng},
   issn = {1179-1322},
   journal = {CANCER MANAGEMENT AND RESEARCH},
   title = {Sequential therapy with bevacizumab and EGFR inhibitors for metastatic colorectal carcinoma: a national registry-based analysis},
   url = {http://dx.doi.org/10.2147/CMAR.S183093},
   volume = {11},
   year = {2019}
}

TY  - JOUR
ID  - 1522176
AU  - Buchler, Tomas - Chloupková, Renata - Poprach, Alexandr - Fiala, Ondrej - Kiss, Igor - Kopeckova, Katerina - Dušek, Ladislav - Veskrnova, Veronika - Slavicek, Lubomir - Kohoutek, Milan - Finek, Jindrich - Svoboda, Marek - Petruzelka, Lubos - Melichar, Bohuslav
PY  - 2019
TI  - Sequential therapy with bevacizumab and EGFR inhibitors for metastatic colorectal carcinoma: a national registry-based analysis
JF  - CANCER MANAGEMENT AND RESEARCH
VL  - 11
IS  - 2019
SP  - 359-368
EP  - 359-368
PB  - DOVE MEDICAL PRESS LTD
SN  - 11791322
KW  - colorectal carcinoma
KW  - bevacizumab
KW  - panitumumab
KW  - cetuximab
KW  - sequence
UR  - http://dx.doi.org/10.2147/CMAR.S183093
L2  - http://dx.doi.org/10.2147/CMAR.S183093
N2  - Purpose: Although inhibitors of vascular endothelial growth factor and inhibitors of epidermal growth factor receptor (EGFRi) are commonly used for the treatment of metastatic colorectal cancer (mCRC), the optimal sequencing of the agents is currently unclear. Methods: A national registry of targeted therapies was used to analyze baseline characteristics and outcomes of patients with mCRC and wild-type KRAS exon 2 status who received bevacizumab and EGFRi (cetuximab or panitumumab) as a part of first- and second-line treatment in either sequence. Results: The cohort included 490 patients (181 patients treated with first-line EGFRi and second-line bevacizumab and 309 patients treated with first-line bevacizumab and second-line EGFRi). Median overall survival (OS) from the initiation on first-line therapy was similar for patients treated with either sequence, reaching 31.8 (95% CI 27.5-36.1) vs 31.4 months (95% CI 27.8-35.0) for EGFRi -> bevacizumab vs bevacizumab -> EGFRi cohort, respectively. Time from first-line initiation to progression on the second-line therapy [progression-free survival (PFS)] was 21.1 (95% CI 19.3-23.0) vs 19.3 months (95% CI 17.3-21.3) for bevacizumab -> EGFRi vs EGFRi -> bevacizumab cohort, respectively (P=0.016). Conclusion: This retrospective analysis of real-world data of patients with wild-type KRAS exon 2 mCRC showed no differences in OS between cohorts treated with bevacizumab -> EGFRi vs the reverse sequence while combined PFS favored the bevacizumab -> EGFRi sequence.
ER  -

BUCHLER, Tomas; Renata CHLOUPKOVÁ; Alexandr POPRACH; Ondrej FIALA; Igor KISS; Katerina KOPECKOVA; Ladislav DUŠEK; Veronika VESKRNOVA; Lubomir SLAVICEK; Milan KOHOUTEK; Jindrich FINEK; Marek SVOBODA; Lubos PETRUZELKA a Bohuslav MELICHAR. Sequential therapy with bevacizumab and EGFR inhibitors for metastatic colorectal carcinoma: a national registry-based analysis. \textit{CANCER MANAGEMENT AND RESEARCH}. ALBANY: DOVE MEDICAL PRESS LTD, 2019, roč.~11, č.~2019, s.~359-368. ISSN~1179-1322. Dostupné z: https://doi.org/10.2147/CMAR.S183093.

Přehled o publikaci